India's Shilpa Medicare can make 100-200 million doses of Covid-19 shot
The company's shares jumped as much as 9.2% on India's National Stock Exchange following the news
 "India's Shilpa Medicare can make 100-200 million doses of Covid-19 shot")
By Sachin Ravikumar
BENGALURU (Reuters) - Indian drugmaker Shilpa Medicare Ltd has the production capacity to make 100-200 million doses of a recombinant vaccine for COVID-19, a company executive told Reuters on Wednesday.
The company's shares jumped as much as 9.2% on India's National Stock Exchange following the news.
(Reporting by Sachin Ravikumar in Bengaluru; Editing by Shounak Dasgupta)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)